JMGMX
Price
$52.21
Change
-$0.21 (-0.40%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

JMGMX vs RPTIX

Header iconJMGMX vs RPTIX Comparison
Open Charts JMGMX vs RPTIXBanner chart's image
JPMorgan Mid Cap Growth R6
Price$52.21
Change-$0.21 (-0.40%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
JMGMX vs RPTIX Comparison Chart
Loading...
VS
JMGMX vs. RPTIX commentary
Sep 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JMGMX is a Buy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. JMGMX (11.1B). RPTIX pays higher dividends than JMGMX: RPTIX (0.18) vs JMGMX (0.00). JMGMX was incepted earlier than RPTIX: JMGMX (13 years) vs RPTIX (9 years). JMGMX is a more actively managed with annual turnover of: 45.00 vs. RPTIX (21.70). RPTIX has a lower initial minimum investment than JMGMX: RPTIX (500000) vs JMGMX (15000000). JMGMX annual gain was more profitable for investors over the last year : 23.63 vs. RPTIX (14.81). JMGMX return over 5 years is better than : 34.78 vs. RPTIX (15.09).
JMGMXRPTIXJMGMX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years9 years-
Gain YTD8.3879.12792%
Front LoadN/AN/A-
Min. Initial Investment150000005000003,000%
Min. Initial Investment IRAN/AN/A-
Net Assets11.1B31.4B35%
Annual Yield % from dividends0.000.18-
Returns for 1 year23.6314.81160%
Returns for 3 years-9.81-13.5772%
Returns for 5 years34.7815.09230%
Returns for 10 years73.69N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp